Our Services
Medical Information
Helpful Resources
Published on: 6/16/2026
After menopause, declining estrogen thins vaginal tissues, causing dryness, painful intercourse, and urinary symptoms — a condition known as genitourinary syndrome of menopause (GSM).
Effective treatments now go far beyond lubricants. Doctors recommend low-dose local estrogen therapy, vaginal DHEA (prasterone), oral ospemifene, non-hormonal moisturizers, and pelvic floor therapy to restore comfort and tissue health.
Because symptoms vary widely and overlap with other conditions, the right next step is understanding your specific pattern. Take a free, instant, online symptom check to clarify what's driving your discomfort and identify which treatments are most likely to help — so you can have a focused, productive conversation with your provider.
Reviewed for medical accuracy: 06/16/2026
Vaginal atrophy—also called genitourinary syndrome of menopause (GSM)—affects up to half of postmenopausal women. Declining estrogen levels thin vaginal tissues, reduce blood flow and lubrication, and alter the pH balance. Common symptoms include dryness, itching, burning, discomfort during intercourse and urinary changes. While over-the-counter lubricants and moisturizers help many women feel more comfortable, doctors now recommend a broader range of therapies to target the root causes of vaginal atrophy.
Women experiencing vaginal atrophy may notice:
These changes can affect intimacy, self-confidence and overall quality of life. If you're experiencing any of these symptoms, you can use Ubie's free AI-powered symptom checker for Atrophic Vaginitis to get personalized insights and understand whether you should seek medical care.
Local (vaginal) estrogen is the gold standard for moderate to severe GSM. It delivers low doses of estrogen directly to vaginal tissues, minimizing systemic exposure.
Forms:
Benefits:
Safety:
Prasterone is an intravaginal insert that converts to estrogens and androgens within vaginal tissues.
How it works:
Advantages:
Usage:
Ospemifene is an oral medication approved specifically for dyspareunia due to GSM.
Mechanism:
Pros and cons:
For women who cannot or prefer not to use hormones, non-hormonal options can provide ongoing relief.
Products:
Benefits:
Pelvic floor therapy can improve muscle tone, blood flow and relaxation, enhancing comfort.
Techniques:
Who can benefit:
In addition to medical treatments, simple lifestyle adjustments can support vaginal health:
Research into new GSM treatments continues:
Discuss these options and their current evidence with your healthcare provider before proceeding.
While many treatments are available, personalized care is key. Speak to a doctor if you experience:
Before your appointment, consider checking your symptoms with Ubie's free Atrophic Vaginitis symptom checker to help you organize your concerns and have a more informed conversation with your healthcare provider.
Important: Nothing in this article replaces professional medical advice. If you have symptoms that could be serious or life-threatening, seek immediate care or call emergency services. Always consult your healthcare provider before starting, changing or stopping any treatment.
By exploring these evidence-based options beyond simple lubricants, women with GSM can regain comfort, function and quality of life. Work closely with your doctor to find the right combination of therapies for your needs.
(References)
* Faubion SS, Larkin LC, Shufelt CL. Genitourinary Syndrome of Menopause (GSM): An Overview of Novel and Emerging Therapies. J Women's Health (Larchmt). 2022 Aug;31(8):1052-1057. doi: 10.1089/jwh.2021.0700. Epub 2022 Jul 11. PMID: 35925000.
* Waheed-Ahmed N, Kaewrudee S, Phupong V. Nonhormonal management of genitourinary syndrome of menopause: a narrative review. Climacteric. 2021 Jun;24(3):218-224. doi: 10.1080/13697137.2020.1866753. Epub 2021 Jan 12. PMID: 34125740.
* Faubion SS, Shufelt CL. Genitourinary Syndrome of Menopause: An Updated Review. Mayo Clin Proc. 2023 Sep;98(9):1428-1439. doi: 10.1016/j.mayocp.2023.04.017. Epub 2023 Jul 11. PMID: 37626356.
* Shufelt CL, Parikh M, Faubion SS. Novel Therapies for Genitourinary Syndrome of Menopause. Curr Probl Diagn Radiol. 2021 May-Jun;50(3):418-422. doi: 10.1067/j.cpradiol.2021.01.002. Epub 2021 Jan 12. PMID: 34091771.
* Tatti F, Seraceno S, Manzi L, et al. Lasers and other nonhormonal approaches for the treatment of genitourinary syndrome of menopause: a comprehensive review. Int Urogynecol J. 2023 Feb;34(2):331-344. doi: 10.1007/s00192-023-05459-z. Epub 2023 Feb 3. PMID: 36737380.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.